LCGC Europe-06-01-2020
Moore’s Law in Liquid Chromatography: An Overview of 50 Years of (U)HPLC
June 1st 2020This article quantifies the progress in speed and efficiency that has been made in the area of liquid chromatography (LC) over the past 50 years. After a decade of groundbreaking advances in the 1970s, the progress in chromatographic performance over the ensuing four decades (1980–now) follows Moore’s law relatively closely. This is characteristic of technological fields that are of an evolutionary nature (that is, driven by the need for better performance).
Advancing Nontargeted Analysis of Water
June 1st 2020Environmental analysis of water presents many challenges, one of which is the potential presence of unknown contaminants. LCGC spoke to Imma Ferrer, an associate research scientist at the University of Colorado, USA, about some of her recent research on nontargeted analysis of water, including water from wastewater treatment plants, hydraulic fracturing wastewater, and environmental water samples.
Recovering from a COVID-19 Shutdown: Tips and Tricks for Starting Up, Part 1
June 1st 2020COVID-19-related laboratory shutdowns are sure to cause a myriad of problems with liquid chromatography (LC) instrumentation across the globe. Taking a systematic approach to restarting these systems will save time and money in the long run, by preventing problems that may otherwise appear in days or weeks following startup.
Stability Studies and Testing of Pharmaceuticals: An Overview
June 1st 2020This instalment is the first in a series of three white papers on stability studies and testing of pharmaceuticals, as well as the development and validation of stability-indicating high performance liquid chromatography (HPLC) methods. The series is co-authored by Kim Huynh-Ba, a subject-matter expert on stability testing and regulatory compliance, and Michael Dong, the columnist on “Perspectives in Modern HPLC”. This first instalment provides a comprehensive and updated overview of stability studies and testing of small molecule drugs, current regulatory requirements, and industry practices for forced degradation, as well as possible approaches for reduced testing and data evaluation to expedite stability study timelines.
